An amended beneficial ownership statement for Inhibrx Biosciences, Inc. (NASDAQ:INBX) director Kristiina Vuori, MD, was filed on September 18, 2026, restating a June 4, 2026 original filing to correct the number of stock options granted due to an administrative error.

Key Highlights

  • Reporting person: Kristiina Vuori, MD, serves as a director of Inhibrx Biosciences, Inc.
  • Transaction date: The stock option grant occurred on June 3, 2026.
  • Options awarded: 10,000 stock options (right to buy) with an exercise price of $95.22 per share were acquired (transaction code A).
  • Vesting date: The options become fully exercisable on June 3, 2027, subject to the reporting person's continued service through that date.
  • Expiration date: The options expire on June 3, 2036.
  • Correction noted: The amendment was filed to correct the number of options granted, which was misstated in the original filing due to an administrative error.
  • Resulting ownership: Vuori beneficially owns 10,000 derivative securities directly following the reported transaction.

Director Option Grant at Inhibrx Biosciences Corrected in Amended Filing

According to the amended filing, Kristiina Vuori, MD, a director at Inhibrx Biosciences, Inc., was granted 10,000 stock options on June 3, 2026, each representing the right to purchase one share of the company's common stock at an exercise price of $95.22. The filing discloses that the price of the derivative security at the time of the transaction was $0, and the options are held directly. Inhibrx Biosciences, headquartered at 11025 N. Torrey Pines Road, Suite 140, La Jolla, California, is a biosciences company traded on NASDAQ:INBX.

The amended statement, signed by Kelly Deck as attorney-in-fact to Kristiina Vuori and dated September 18, 2026, restates the original Form 4 filed on June 4, 2026 "in its entirety to correct the number of options granted to the Reporting Person due to an administrative error," according to the filing's remarks section. The options will be fully exercisable on June 3, 2027, contingent on the reporting person's continued service through that date, as noted in the explanation of responses. The options carry a ten-year term, expiring on June 3, 2036.

What Was Disclosed

The amended filing discloses a corrected stock option grant of 10,000 shares to director Kristiina Vuori, MD, at an exercise price of $95.22, with a vesting date of June 3, 2027 and expiration of June 3, 2036. The amendment corrects an administrative error in the original filing.